311 related articles for article (PubMed ID: 24766216)
21. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
22. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC
Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282
[TBL] [Abstract][Full Text] [Related]
23. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
24. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
[TBL] [Abstract][Full Text] [Related]
25. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
26. Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.
Ishikawa C; Mori N
Invest New Drugs; 2022 Aug; 40(4):718-727. PubMed ID: 35477814
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and therapeutic significance of XPO1 in T-cell lymphoma.
Nie D; Xiao X; Chen J; Xie S; Xiao J; Yang W; Liu H; Wang J; Ma L; Du Y; Huang K; Li Y
Exp Cell Res; 2022 Jul; 416(2):113180. PubMed ID: 35489384
[TBL] [Abstract][Full Text] [Related]
28. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.
Gao J; Azmi AS; Aboukameel A; Kauffman M; Shacham S; Abou-Samra AB; Mohammad RM
Oncotarget; 2014 Jun; 5(11):3444-54. PubMed ID: 24899509
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation.
Zhao C; Ma B; Yang ZY; Li O; Liu SL; Pan LJ; Gong W; Dong P; Shu YJ
Cancer Med; 2023 Mar; 12(5):5751-5763. PubMed ID: 36200270
[TBL] [Abstract][Full Text] [Related]
31. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.
Cheng Y; Holloway MP; Nguyen K; McCauley D; Landesman Y; Kauffman MG; Shacham S; Altura RA
Mol Cancer Ther; 2014 Mar; 13(3):675-86. PubMed ID: 24431073
[TBL] [Abstract][Full Text] [Related]
32. Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication.
Mathew C; Tamir S; Tripp RA; Ghildyal R
Sci Rep; 2021 Sep; 11(1):19223. PubMed ID: 34584169
[TBL] [Abstract][Full Text] [Related]
33. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
Schmidt J; Braggio E; Kortuem KM; Egan JB; Zhu YX; Xin CS; Tiedemann RE; Palmer SE; Garbitt VM; McCauley D; Kauffman M; Shacham S; Chesi M; Bergsagel PL; Stewart AK
Leukemia; 2013 Dec; 27(12):2357-65. PubMed ID: 23752175
[TBL] [Abstract][Full Text] [Related]
35. Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer.
Aladhraei M; Kassem Al-Thobhani A; Poungvarin N; Suwannalert P
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3747-3754. PubMed ID: 31870117
[TBL] [Abstract][Full Text] [Related]
36. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
37. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
38. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
[TBL] [Abstract][Full Text] [Related]
39. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
[TBL] [Abstract][Full Text] [Related]
40. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
